Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults
Latest Information Update: 20 Mar 2024
At a glance
- Drugs Elasomeran (Primary) ; MRNA-1010 (Primary) ; MRNA-1345 (Primary) ; MRNA-1647 (Primary)
- Indications COVID 2019 infections; Cytomegalovirus infections; Influenza virus infections; Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors Moderna Therapeutics
- 15 Mar 2024 Planned End Date changed from 25 Mar 2024 to 21 Feb 2026.
- 15 Mar 2024 Planned primary completion date changed from 25 Mar 2024 to 21 Feb 2026.
- 13 Mar 2023 Planned End Date changed from 30 Nov 2023 to 25 Mar 2024.